Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents ORIGINAL CONTRIBUTION Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF- Agents Anja Strangfeld, MD Context The risk of bacterial infection is increased in patients treated with drugs that Joachim Listing, PhD inhibit tumor necrosis factor  (TNF-). Little is known about the reactivation of la- tent viral infections during treatment with TNF- inhibitors. Peter Herzer, MD Objective To investigate whether TNF- inhibitors together as a class, or separately Anke Liebhaber, MD as either monoclonal anti–TNF- antibodies (adalimumab, infliximab) or a fusion pro- Karin Rockwitz, MD tein (etanercept), are related to higher rates of herpes zoster in patients with rheu- matoid arthritis. Constanze Richter, MD Design, Setting, and Patients Patients were enrolled in the German biologics reg- Angela Zink, PhD ister RABBIT, a prospective cohort, between May 2001 and December 2006 at the initia- NHIBITION OF TUMOR NECROSIS FAC- tionoftreatmentwithinfliximab,etanercept,adalimumab,oranakinra,orwhentheychanged conventional disease-modifying antirheumatic drug (DMARD). Treatment, clinical status, tor  (TNF-) has been shown ef- and adverse events were assessed by rheumatologists at fixed points during follow-up. fective in the treatment of patients Iwith active rheumatoid arthritis. For Main Outcome Measures Hazard ratio (HR) of herpes zoster episodes following patients in whom the disease activity can- http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

Loading next page...
 
/lp/american-medical-association/risk-of-herpes-zoster-in-patients-with-rheumatoid-arthritis-treated-Bv9Wm2YtOF

References (51)

Publisher
American Medical Association
Copyright
Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2009.146
pmid
19224750
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL CONTRIBUTION Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF- Agents Anja Strangfeld, MD Context The risk of bacterial infection is increased in patients treated with drugs that Joachim Listing, PhD inhibit tumor necrosis factor  (TNF-). Little is known about the reactivation of la- tent viral infections during treatment with TNF- inhibitors. Peter Herzer, MD Objective To investigate whether TNF- inhibitors together as a class, or separately Anke Liebhaber, MD as either monoclonal anti–TNF- antibodies (adalimumab, infliximab) or a fusion pro- Karin Rockwitz, MD tein (etanercept), are related to higher rates of herpes zoster in patients with rheu- matoid arthritis. Constanze Richter, MD Design, Setting, and Patients Patients were enrolled in the German biologics reg- Angela Zink, PhD ister RABBIT, a prospective cohort, between May 2001 and December 2006 at the initia- NHIBITION OF TUMOR NECROSIS FAC- tionoftreatmentwithinfliximab,etanercept,adalimumab,oranakinra,orwhentheychanged conventional disease-modifying antirheumatic drug (DMARD). Treatment, clinical status, tor  (TNF-) has been shown ef- and adverse events were assessed by rheumatologists at fixed points during follow-up. fective in the treatment of patients Iwith active rheumatoid arthritis. For Main Outcome Measures Hazard ratio (HR) of herpes zoster episodes following patients in whom the disease activity can-

Journal

JAMAAmerican Medical Association

Published: Feb 18, 2009

There are no references for this article.